- Home
- RIGL vs RGNX Comparison
RIGL vs RGNX Comparison
Compare RIGL & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- RGNX
- Stock Information
- Founded
- RIGL 1996
- RGNX 2008
- Country
- RIGL United States
- RGNX United States
- Employees
- RIGL N/A
- RGNX N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RIGL Health Care
- RGNX Health Care
- Exchange
- RIGL Nasdaq
- RGNX Nasdaq
- Market Cap
- RIGL 366.5M
- RGNX 387.0M
- IPO Year
- RIGL 2000
- RGNX 2015
- Fundamental
- Price
- RIGL $17.17
- RGNX $6.69
- Analyst Decision
- RIGL Buy
- RGNX Strong Buy
- Analyst Count
- RIGL 5
- RGNX 9
- Target Price
- RIGL $36.80
- RGNX $32.89
- AVG Volume (30 Days)
- RIGL 253.6K
- RGNX 1.0M
- Earning Date
- RIGL 03-04-2025
- RGNX 05-07-2025
- Dividend Yield
- RIGL N/A
- RGNX N/A
- EPS Growth
- RIGL N/A
- RGNX N/A
- EPS
- RIGL 0.99
- RGNX N/A
- Revenue
- RIGL $179,278,000.00
- RGNX $83,328,000.00
- Revenue This Year
- RIGL $14.19
- RGNX $285.14
- Revenue Next Year
- RIGL $13.10
- RGNX N/A
- P/E Ratio
- RIGL $17.17
- RGNX N/A
- Revenue Growth
- RIGL 54.71
- RGNX N/A
- 52 Week Low
- RIGL $7.48
- RGNX $5.62
- 52 Week High
- RIGL $29.82
- RGNX $21.19
- Technical
- Relative Strength Index (RSI)
- RIGL 34.02
- RGNX 45.81
- Support Level
- RIGL $17.01
- RGNX $7.96
- Resistance Level
- RIGL $19.97
- RGNX $8.35
- Average True Range (ATR)
- RIGL 1.01
- RGNX 0.67
- MACD
- RIGL -0.29
- RGNX 0.04
- Stochastic Oscillator
- RIGL 10.65
- RGNX 37.99
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.